Daily Endocrinology Research Analysis
Analyzed 73 papers and selected 3 impactful papers.
Summary
Three clinically oriented endocrinology papers stood out today: a validated bone–puberty integrated model markedly improves adult height prediction; a BMI-stratified, body-weight–optimized model refines levothyroxine dosing after thyroidectomy; and non-tablet levothyroxine formulations in pregnancy reached TSH targets with lower doses than tablets. Together, they advance precision dosing and prediction in pediatric and thyroid endocrinology.
Research Themes
- Growth prediction tools in pediatric endocrinology
- Precision dosing strategies for levothyroxine
- Formulation-dependent pharmacotherapy in pregnancy
Selected Articles
1. Clinically Optimized Adult Height Prediction From Key Bone and Pubertal Stages: Prospective Validation to Adult Height.
Using key bone grades (radius and metacarpal I preferred) combined with pubertal stage, the model directly mapped skeletal/pubertal status to remaining growth. In independent validation to adult height, mean prediction error decreased from 0.71 cm to 0.02 cm, and the proportion of predictions within 3 cm increased from 66.9% to 73.5%.
Impact: Provides a practical, accurate, two-bone protocol that outperforms traditional bone-age methods and is validated to adult height, enabling streamlined clinical workflows.
Clinical Implications: Facilitates faster, more accurate height counseling and decision-making in pediatric endocrinology (e.g., timing of interventions), potentially reducing reliance on full bone age assessments and specialized software.
Key Findings
- Key bone combinations (radius + ulna, radius + metacarpal I, radius + ulna + metacarpal I) with pubertal stage yielded similar performance.
- Preferred clinically optimized model: radius + metacarpal I plus pubertal stage.
- Independent validation showed mean prediction error reduction from 0.71 cm to 0.02 cm and increased within-3 cm accuracy from 66.9% to 73.5%.
Methodological Strengths
- Independent validation cohort followed to adult height
- Direct mapping of skeletal/pubertal status to growth potential with simple, feasible two-bone protocol
Limitations
- Exact sample sizes for development and validation are not specified in the abstract
- Cross-sectional development design may limit causal inferences; generalizability across populations requires confirmation
Future Directions: Prospective, multi-center validation across diverse ethnicities; integration into clinical decision support; comparison against AI-based bone age systems.
CONTEXT: Accurate adult height prediction remains a challenge in pediatric endocrinology. Traditional bone age (BA) based methods are time-consuming, software-dependent, and unreliable, while ignoring the critical effect of pubertal progression on growth potential. OBJECTIVE: In this work we aimed to develop a clinically optimized model for adult height prediction by replacing traditional BA with key bone grades to quantify growth potential, integrating pubertal stages to account for pubertal-stage growth variations, and establishing a direct mapping between "key bone grades + pubertal stage" and height growth potential. METHODS: A cross-se
2. Levothyroxine dose prediction post-thyroidectomy for differentiated thyroid carcinoma.
In 385 thyroidectomy patients, higher BMI demanded greater total daily L‑T4 but lower µg/kg dosing. An optimized, BMI‑stratified model using body-weight metrics (with adjusted body weight emerging as the best predictor in normal BMI) improved dose prediction and accuracy for achieving TSH targets within the first postoperative year.
Impact: Provides a practical, validated dosing framework that reduces misdosing in overweight/obese patients and accelerates TSH suppression while mitigating adverse effects.
Clinical Implications: Adopt BMI-stratified dosing using optimized body weight metrics (e.g., adjusted body weight) rather than simple total body weight to set initial L‑T4 doses post-thyroidectomy, then titrate to TSH targets.
Key Findings
- Postoperative TSH levels varied significantly by BMI category.
- Higher BMI required higher total daily L‑T4 but lower weight‑adjusted doses.
- BMI‑stratified models using optimized body weight metrics (adjusted body weight best in normal BMI) improved dose prediction accuracy (hold‑out validation).
Methodological Strengths
- Relatively large single-center cohort (n=385) with prespecified TSH targets
- Internal hold-out validation of regression models across multiple body-weight metrics
Limitations
- Retrospective, single-center design limits generalizability
- Abstract truncation leaves incomplete detail on model coefficients and performance by BMI strata
Future Directions: Prospective, multi-center external validation; development of bedside calculators/EMR integration; evaluation across ethnicities and iodine nutrition backgrounds.
OBJECTIVE: To address the overestimation of levothyroxine (L-T4) doses in conventional weight-based regimens for individuals who are overweight and obese, this study aimed to identify the most predictive body weight metrics and establish an optimized dosing model for accurate thyroid-stimulating hormone (TSH) suppression following total thyroidectomy in differentiated thyroid carcinoma (DTC). METHODS: This retrospective study included 385 patients with DTC treated at our institution between October 2019 and December 2024. Patients were stratified by TSH targets (A1: <0.1 mIU/L; A2: 0.1-0.5 mIU/L; A3: 0.5-2.0 mIU/L) and body mass index (BMI) according to Chinese criteria (normal: <24 kg/m²; overweight: 24-27.9 kg/m²; obesity: ≥28 kg/m²). Linear regression analysis was used to analyze correlations between the final stable L-T4 dose and weight metrics, including total body weight, adjusted body weight, lean body weight, ideal body weight, and body surface area, followed by model validation. Model performance was internally validated using a hold-out method. Efficacy was estimated as the accuracy of the model-predicted dose compared with the actual dose required when a patient first achieved their TSH target within the first postoperative year. RESULTS: The baseline characteristics showed no significant intergroup differences (P>0.05). Postoperative TSH levels varied significantly according to BMI (P<0.05). Patients with higher BMI required higher total L-T4 doses (µg/d) (P<0.001) but lower weight-adjusted doses (µg/kg/d) (P<0.001). Adjusted body weight best predicted L-T4 dose for patients with BMI ≤ 23.9 kg/m CONCLUSION: The BMI-stratified L-T4 dosing formula based on optimized body weight metrics demonstrated improved accuracy, expediting TSH suppression and reducing adverse events.
3. Do levothyroxine adjustments during pregnancy differ between users of tablet and non-tablet formulation? A real-world study.
In pregnant women with hypothyroidism (especially non-post-thyroidectomy), both LT4 dose and formulation independently predicted achieving TSH ≤2.5 μIU/mL by midpregnancy. Non-tablet formulations required lower doses (1.5 vs 2.4 μg/kg/day for 90% success probability), suggesting therapeutic superiority over tablets.
Impact: Highlights the clinical relevance of formulation choice in pregnancy and supports considering non-tablet LT4 to achieve guideline TSH targets with lower doses.
Clinical Implications: For pregnant patients with hypothyroidism, consider non-tablet LT4 formulations to reach TSH targets with lower doses, while individualizing based on weight, thyroid volume, and etiology.
Key Findings
- In non-post-thyroidectomy hypothyroidism, LT4 dose and formulation independently predicted achieving TSH ≤2.5 μIU/mL.
- Non-tablet LT4 required lower doses to reach a 90% probability of TSH target (1.5 vs 2.4 μg/kg/day).
- Formulation choice remained significant after adjustment for maternal weight and thyroid volume.
Methodological Strengths
- Real-world cohort with standardized TSH monitoring every 30–40 days until midpregnancy
- Multivariable modeling accounting for key confounders (weight, thyroid volume, etiology)
Limitations
- Retrospective single-center design limits causal inference
- Generalizability to post-thyroidectomy hypothyroidism and across different non-tablet formulations requires further study
Future Directions: Randomized or prospective comparative studies of tablet vs non-tablet LT4 in pregnancy; pharmacokinetic/pharmacodynamic profiling by formulation.
OBJECTIVE: We aimed to assess the levothyroxine (LT4) dosage needed to achieve a target thyrotropin (TSH) ≤ 2.5 μIU/mL in LT4 tablet and non-tablet users during the first half of pregnancy. METHODS: We conducted a retrospective analysis on pregnant women with hypothyroidism on LT4 at our university hospital over a period of four years. Inclusion criteria were: a) 0.5 μIU/mL < TSH < 4.0 μIU/mL after the first visit; availability of serum TSH every 30-40 days until midpregnancy; correct LT4 intake and compliance. Predictors of achieving TSH ≤ 2.5 μIU/mL were explored using a multivariable probit regression model. P- value lower than 0.05 was considered statistically significant. RESULTS: We included 212 pregnant women (185 with non-post-thyroidectomy hypothyroidism and 27 with post-thyroidectomy hypothyroidism) on LT4 [tablet in 132 women (62.3%), while non-tablet in 80 women (37.7%)]. In non-post-thyroidectomy hypothyroidism, the adjusted analysis, accounting for confounders (i.e., maternal weight, thyroid volume and type of hypothyroidism), revealed that both LT4 dose (p=0.001) and formulation (p=0.036) were independent and significant predictors of achieving the TSH target. In non-post-thyroidectomy hypothyroidism, the required dose to achieve a 90% probability of success (TSH ≤ 2.5 μIU/mL) was lower for the non-tablet group (1.5 μg/kg/day; 95% CI: 0.47-2.62) than for the tablet group (2.4 μg/kg/day; 95% CI: 1.8-5.6). CONCLUSIONS: In pregnant women with non-post-thyroidectomy hypothyroidism lower LT4 dosages may be necessary to achieve TSH between 0.5 μIU/mL < TSH ≤ 2.5 μIU/mL with LT4 non-tablet compared to tablet formulations (therapeutic superiority).